Clinical Trial Update: Phase II Clinical Trial of OCH-NCNP1 [Phase 2]

View source ↗

Summary

Phase II clinical trial update for OCH-NCNP1 completed; study conditions include relapsing-remitting and secondary progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• OCH-NCNP1

Snippet

Sponsor: National Center of Neurology and Psychiatry, Japan | Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 2 | Status: COMPLETED